Table 1.
Baseline Characteristics of Patients in the Biomarker Analysis vs Others
| Patients With All Biomarker Readings at Baseline | All Other Patients | P Value* | |
|---|---|---|---|
| 7863 (100%) | 1151 (100%) | ||
| Pravastatin, No. (%) | 3941 (50) | 571 (50) | |
| Age at randomization, y, median (IQR) | 62.0 (55.0 to 67.0) | 61.0 (54.0 to 67.0) | <0.001 |
| Age ≥65 y, No. (%) | 3109 (40) | 405 (35) | <0.01 |
| Female, No. (%) | 1333 (17) | 183 (16) | 0.37 |
| Baseline health | |||
| Months from QE, median (IQR) | 13.9 (7.9 to 25.0) | 12.8 (7.6 to 24.0) | 0.03 |
| Current smoker, No. (%) | 735 (9) | 134 (12) | 0.01 |
| Hypertension, No. (%) | 3291 (42) | 467 (41) | 0.41 |
| Diabetes, No. (%) | 676 (9) | 106 (9) | 0.49 |
| Obese, No. (%) | 1397 (18) | 214 (19) | 0.50 |
| Stroke, No. (%) | 322 (4) | 47 (4) | 0.99 |
| Atrial fibrillation, No. (%) | 110 (1) | 13 (1) | 0.46 |
| Systolic BP, mean (SD), mm Hg | 134 (19) | 133 (18) | 0.11 |
| Diastolic BP, mean (SD), mm Hg | 81 (11) | 80 (11) | 0.64 |
| Dyspnea NYHA Class >1, No. (%) | 761 (10) | 97 (8) | 0.18 |
| Angina CCS Grade >0, No. (%) | 2927 (37) | 401 (35) | 0.12 |
| Baseline lipids | |||
| Total cholesterol, mean (SD), nmol/L | 5.7 (0.8) | 5.6 (0.8) | 0.03 |
| Total cholesterol ≥5.5 mmol/L, No. (%) | 4495 (57) | 639 (56) | 0.29 |
| LDL‐C, mean (SD), nmol/L | 3.9 (0.7) | 3.8 (0.7) | <0.01 |
| LDL‐C ≥3.5 mmol/L, No. (%) | 5513 (70) | 780 (68) | 0.11 |
| HDL‐C, mean (SD), nmol/L | 1.0 (0.2) | 1.0 (0.2) | 0.84 |
| HDL‐C ≥1 mmol/L, No. (%) | 2936 (37) | 422 (37) | 0.67 |
| Triglyceride, median (IQR), nmol/L | 1.6 (1.2 to 2.2) | 1.6 (1.2 to 2.2) | 0.39 |
| Total cholesterol:HDL‐C, mean (SD), nmol/L | 6.2 (1.5) | 6.2 (1.5) | 0.37 |
| eGFR, median (IQR), mLs/min | 69 (60 to 80) | 70 (60 to 81) | 0.56 |
| WBC, median (IQR) ×109 | 7.0 (6.0 to 8.2) | 7.1 (6.0 to 8.3) | 0.30 |
| Previous coronary revascularization | |||
| No revascularization, No. (%) | 4610 (59) | 712 (62) | 0.03 |
| PCI only, No. (%) | 870 (11) | 118 (10) | — |
| CABG only, No. (%) | 2141 (27) | 295 (26) | — |
| PCI and CABG, No. (%) | 242 (3) | 26 (2) | — |
| Qualifying Event | |||
| No MI, No. (%) | 2843 (36) | 417 (36) | 0.90 |
| Single MI, No. (%) | 4115 (52) | 604 (52) | — |
| Multiple MI, No. (%) | 905 (12) | 130 (11) | — |
| Medications | |||
| Aspirin, No. (%) | 6501 (83) | 901 (78) | <0.001 |
| ACE inhibitors, No. (%) | 1254 (16) | 179 (16) | 0.73 |
| β‐Blocker, No. (%) | 3691 (47) | 538 (47) | 0.90 |
| Calcium antagonist, No. (%) | 2688 (34) | 424 (37) | 0.08 |
| LIPID risk score, mean (SD)10 | 5.8 (3.5) | 6.0 (3.5) | 0.26 |
No. (%) is presented unless otherwise stated. ACE indicates angiotensin‐converting enzyme; BP, blood pressure; CABG, coronary artery bypass graft surgery; CCS, Canadian Cardiovascular Society; eGFR, estimated glomerular filtration rate; HDL‐C, HDL cholesterol; IQR, interquartile range; LDL‐C, LDL cholesterol; LIPID, Long‐term Intervention with Pravastatin in Ischaemic Disease; MI, myocardial infarction, NYHA, New York Heart Association; PCI, percutaneous coronary intervention; WBC, white blood cell count.
*
P‐values for continuous variables are from a linear model, and for categorical variables are from an ordinal or logistic regression.